CD44 and cancer: In one study, the redox-active ferrocene (Fc) containing Fc-GQD-HA, a biocompatible formulation, was found to target specifically CD44 over-expressing cancer cells with ~ threefold oxidative-stress-mediated Hela cell death [155].